文献速递白血病

儿童急性淋巴细胞白血病中门冬酰胺酶的个体化给药

Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2020-01-10

在DCOG ALL-11方案中,对儿童急性淋巴细胞白血病采用治疗药物监测(TDM)个体化PEG门冬酰胺酶和欧文菌门冬酰胺酶治疗。TDM使PEG门冬酰胺酶最终中位剂量降至450 IU/m2,97%非过敏患者谷浓度>100 IU/L,且天冬酰胺耗竭充分;但降低酶活性对毒性影响有限。

要点

  • TDM使PEG门冬酰胺酶中位剂量降至450 IU/m2,97%谷浓度>100 IU/L。
  • PEG门冬酰胺酶谷浓度>100 IU/L时96%天冬酰胺<0.5 μM。
  • 10%发生中和性过敏反应,其中40%为沉默性失活。

核心结论

  • 门冬酰胺酶TDM可显著降低PEG门冬酰胺酶剂量,同时维持足够的酶活性和天冬酰胺耗竭。
  • TDM可识别沉默性失活和过敏样反应,但降低酶活性对毒性的影响有限。

研究设计与样本

  • DCOG ALL-11方案中,中危患者(n=243)接受14次个体化剂量,目标谷浓度100-250 IU/L。
  • 标危患者(n=108)接受1次个体化剂量,高危患者(n=18)接受2-5次固定给药(1,500 IU/m2)。
  • 发生中和性过敏反应后,改用欧文菌门冬酰胺酶20,000 IU/m2每周3次,并监测l-天冬酰胺。

主要发现

  • PEG门冬酰胺酶最终中位剂量降至450 IU/m2,97%非过敏患者谷浓度>100 IU/L。
  • PEG门冬酰胺酶和欧文菌门冬酰胺酶谷浓度>100 IU/L时,天冬酰胺<0.5 μM的比例分别为96%和67%。
  • 10%发生中和性过敏反应,其中40%为沉默性失活。
  • 3-4级胰腺炎、中枢神经毒性和血栓的累积发生率分别为12%、4%和6%,与门冬酰胺酶活性水平无关。
  • 中危强化治疗期间,50%出现ALT升高和3%高胆红素血症(均为3/4级,与酶活性相关),37%发生3/4级高甘油三酯血症。

关键数值与推荐

  • PEG门冬酰胺酶目标谷浓度100-250 IU/L。
  • 欧文菌门冬酰胺酶剂量20,000 IU/m2每周3次。
  • 天冬酰胺<0.5 μM作为耗竭指标。

临床怎么用

  • 按TDM调整PEG门冬酰胺酶剂量,维持谷浓度>100 IU/L以确保疗效。
  • 监测天冬酰胺水平以识别沉默性失活,及时换用欧文菌门冬酰胺酶。
  • 关注强化治疗期间肝毒性和高甘油三酯血症,其与酶活性水平相关。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the DCOG ALL-11 protocol, polyethylene glycol-conjugated Escherichia coli asparaginase (PEGasparaginase) and Erwinia asparaginase treatment of pediatric acute lymphoblastic leukemia are individualized with therapeutic drug monitoring (TDM). The efficacy of TDM and its effect on asparaginase-associated toxicity are reported. PATIENTS AND METHODS: After induction with 3 fixed intravenous doses of 1,500 IU/m2 PEGasparaginase, medium-risk patients (n = 243) received 14 individualized doses that targeted trough levels of 100-250 IU/L, standard-risk patients (n = 108) received 1 individualized dose, and high-risk patients (n = 18) received 2-5 fixed administrations (1,500 IU/m2). After a neutralizing hypersensitivity reaction, patients were started with 20,000 IU/m2 Erwinia asparaginase 3 times per week, and l-asparagine was measured to monitor asparaginase efficacy. Several asparaginase-associated toxicities were studied. RESULTS: The final median PEGasparaginase dose was lowered to 450 IU/m2. Overall, 97% of all trough levels of nonallergic patients were > 100 IU/L. Asparagine was < 0.5 μM in 96% and 67% of the PEGasparaginase and Erwinia asparaginase levels > 100 IU/L, respectively. Ten percent developed a neutralizing hypersensitivity reaction to PEGasparaginase, of which 40% were silent inactivations. The cumulative incidence of grade 3-4 pancreatitis, central neurotoxicity, and thromboses was 12%, 4%, and 6%, respectively, and not associated with asparaginase activity levels. During medium-risk intensification, 50% had increased ALT and 3% hyperbilirubinemia (both grade 3/4 and correlated with asparaginase activity levels), and 37% had grade 3/4 hypertriglyceridemia. Hypertriglyceridemia occurred less in intensification compared with ALL-10 (37% v 47%), which is similar to ALL-11 but with higher asparaginase levels during intensification. CONCLUSION: TDM of asparaginase results in a significant reduction of the PEGasparaginase dose with adequate asparaginase activity levels and sufficient asparagine depletion. In addition, with TDM, silent inactivation and allergic-like reactions were identified. However, the effect of reduced asparaginase activity levels on toxicity is limited.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kloos RQH, Pieters R, Jumelet FMV, et al. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia. J Clin Oncol. 2020. PMID: 31922920. doi:10.1200/JCO.19.02292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。